MedChemExpress LLC (MCE)

MedChemExpressModel Odronextamab -1801338-64-6

SHARE
Odronextamab is a stable humanized IgG4 CD20 × CD3 bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering anti-tumor activity. Odronextamab is expected to be used in oncology research[1].
Most popular related searches

MCE products for research use only. We do not sell to patients.

Odronextamab

MCE China:Odronextamab

Brand:MedChemExpress (MCE)

Cat. No.HY-P99038

CAS:1801338-64-6

Purity:99.50%

Storage:Please store the product under the recommended conditions in the Certificate of Analysis.

Shipping:Shipping with dry ice.

Description:Odronextamab is a stable humanized IgG4 CD20 × CD3 bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering anti-tumor activity. Odronextamab is expected to be used in oncology research.

In Vitro:Odronextamab (1-10 nM, 48-96 h) at a low picomolar concentration, mediates cytotoxicity of all tested CD20-expressing lymphoma cells[2].

In Vivo:Odronextamab (0.4-1 mg/kg, administered via intraperitoneal injection, single dose) exhibits dose-dependent tumor-suppressive activity in a mouse tumor model[2].

Species:Bispecific

Isotype:Human IgG4 kappa

Recommend Isotype Controls:Human IgG4 (S228P) kappa, Isotype Control

Hot selling product:4-Chloro-7H-pyrrolo[2,3-d]pyrimidine  | SPB  | Tamibarotene  | CITCO  | Relugolix  | Cefoperazone  | LCMV gp33-41  | H-Phe(4-Ac)-OH  | 3-Nitropropanoic acid  | Demeclocycline

Trending products:Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

References:

[1]. Rajat Bannerji, et al. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet H  [Content Brief]

[2]. Zhu M, et al. Translational findings for odronextamab: From preclinical research to a first-in-human study in patients with CD20+ B-cell malignancies. Clin Transl Sci. 2022 Apr;15(4):954-966.  [Content Brief]

Brand introduction:
•   MCE (MedChemExpress) has a global exclusive compound library of more than 200 kinds, and we are committed to providing the most comprehensive range of high-quality small molecule active compounds for scientific research customers around the world;
•   More than 50,000 highly selective inhibitors and agonists are involved in various popular signaling pathways and disease areas;
•   The products cover a variety of recombinant proteins, peptides, commonly used kits, more PROTAC, ADC and other characteristic products, widely used in new drug research and development, life science and other scientific research projects;
•   Provide virtual screening, ion channel screening, metabolomics analysis detection analysis, drug screening and other professional technical services;
•   It has a professional experimental center and strict quality control and verification system;
•   Provide LC/MS, NMR, HPLC, chiral analysis, elemental analysis and other quality inspection reports to ensure the high purity and high quality of products;
•   The biological activity of the products has been verified by the experiments of customers in various countries;
•   A variety of top journals such as Nature, Cell, Science and pharmaceutical patents have included the scientific research results of MCE customers;
•   Our professional team tracks the latest pharmaceutical and life science research and provides you with the latest active compounds in the world;
•   It has established long-term cooperation with the world's major pharmaceutical companies and well-known scientific research institutions。